Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (HK:6990) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has inked a deal with China Resources Kelun to distribute its late-stage pipeline products in China, marking a strategic step in its commercialization efforts. This non-exclusive agreement positions China Resources Kelun to act as a distributor, enhancing access to downstream distributors and end customers. The transaction aligns with listing rules and is subject to reporting but doesn’t require independent shareholder approval.
For further insights into HK:6990 stock, check out TipRanks’ Stock Analysis page.